3D Medicines Inc. announced that on October 28, 2023, first commercial drug (Envafolimab) has received an approval from the U.S. Food and Drug Administration (the "FDA") to proceed with phase III Multinational, Multicenter, Randomized, Open label, Clinical Study Comparing Envafolimab plus Lenvatinib Versus Carboplatin paclitaxel as First Line Therapy in Subjects with Mismatch Repair Proficient (pMMR) Advanced or Recurrent Endometrial Cancer. The approval marks significant progress in global development.